Literature DB >> 18281511

Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.

Aime A Levesque1, Andrew A Fanous, Alissa Poh, Alan Eastman.   

Abstract

DNA damage induces cell cycle arrest to provide time for repair and enhance cell survival. The Chk1 inhibitor 7-hydroxystaurosporine (UCN-01) can overcome both S and G(2) arrest and drive cells through a lethal mitosis. S-phase arrest induced by the topoisomerase I inhibitor SN38 results from activation of Chk1 and degradation of Cdc25A phosphatase that occurs independent of p53 status. However, p53-mediated induction of p21(waf1) and repression of cyclin B prevent abrogation of S and G(2) arrest, respectively. Surprisingly, incubation of MCF10A immortalized breast cells with UCN-01 fails to elevate Cdc25A protein due to p53-mediated inhibition of Cdc25A transcription. Suppression of p21(waf1) in MCF10A cells overcame this transcriptional inhibition, and the S-phase-arrested cells became sensitive to UCN-01, although they now arrested in G(2) as cyclin B expression remained suppressed. We also compared the response of p53 wild-type tumors to the combination of SN38 and UCN-01. In CAKI-1, U87MG, and SUM102, SN38 induced p21(waf1) and the cells were resistant to UCN-01. In contrast, HCT116 and MCF7 cells had markedly attenuated induction of p21(waf1) and failed to repress cyclin B. Accordingly, these cells were susceptible to UCN-01-mediated abrogation of both S and G(2) arrest. SN38 induced expression of another p53-inducible gene, 14-3-3sigma, suggesting selective dysregulation of p53 response genes. In summary, several cell lines commonly considered wild-type for p53 appear to have defects in expression of selected p53 response genes following DNA damage, and this makes them sensitive to the combination of DNA damage plus Chk1 inhibitor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281511     DOI: 10.1158/1535-7163.MCT-07-2066

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  22 in total

1.  PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.

Authors:  Crissy Dudgeon; Peng Wang; Xiameng Sun; Rui Peng; Quanhong Sun; Jian Yu; Lin Zhang
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

2.  Radiotherapy in conjunction with 7-hydroxystaurosporine: a multimodal approach with tumor pO2 as a potential marker of therapeutic response.

Authors:  Nadeem Khan; Sriram P Mupparaju; Huagang Hou; Jean P Lariviere; Eugene Demidenko; Harold M Swartz; Alan Eastman
Journal:  Radiat Res       Date:  2009-11       Impact factor: 2.841

3.  Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.

Authors:  C Blattmann; S Oertel; M Thiemann; K J Weber; P Schmezer; O Zelezny; R Lopez Perez; A E Kulozik; J Debus; V Ehemann
Journal:  Strahlenther Onkol       Date:  2012-01-18       Impact factor: 3.621

4.  Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.

Authors:  Svetlana Grabauskiene; Edward J Bergeron; Guoan Chen; Dafydd G Thomas; Thomas J Giordano; David G Beer; Meredith A Morgan; Rishindra M Reddy
Journal:  J Surg Res       Date:  2013-12-18       Impact factor: 2.192

5.  Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.

Authors:  Ryan Montano; Injae Chung; Kristen M Garner; David Parry; Alan Eastman
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

6.  Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.

Authors:  Wei-Hsun Hsu; Xiaoliang Zhao; Jianquan Zhu; In-Kyu Kim; Guanhua Rao; Justine McCutcheon; Shuo-Tse Hsu; Beverly Teicher; Bhaskar Kallakury; Afshin Dowlati; Yu-Wen Zhang; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2019-02-14       Impact factor: 15.609

7.  Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.

Authors:  Li-Ju Chang; Alan Eastman
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

8.  Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.

Authors:  Sean Vance; Erqi Liu; Lili Zhao; Joshua D Parsels; Leslie A Parsels; Jeffery L Brown; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

Review 9.  Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.

Authors:  Cynthia X Ma; James W Janetka; Helen Piwnica-Worms
Journal:  Trends Mol Med       Date:  2010-11-17       Impact factor: 11.951

10.  Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.

Authors:  Lei Duan; Ricardo E Perez; Michael Hansen; Steven Gitelis; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.